+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating a new way to deliver treatment using the ECAP-controlled closed-loop spinal cord stimulation SCS system called the Evoke System. This study focuses on patients who experience chronic pain in the trunk andor limbs. The goal is to test and assess new software and hardware features that may improve how the Evoke System delivers treatment. Participants will use the Evoke Spinal Cord Stimulation System, which measures electrical activity called evoked compound action potentials ECAPs. The device automatically adjusts the stimulation current to keep the ECAP amplitude consistent. This study involves a single group of participants using this novel device and will continue through to study completion, which may last up to two years. During the study, participants will be monitored for changes in ECAPs measured by the Evoke System. Researchers will evaluate these changes over the course of the study to understand how the device functions with the new features. Participants will need to provide informed consent and comply with study requirements while using the device. The total participation time can last up to two years, with regular assessments conducted throughout this period.

Age: 18Years +All GendersPhase Not Applicable
25 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether expanding the use of finger-stick point-of-care testing for hepatitis C virus HCV can improve diagnosis and treatment rates among people at risk for HCV infection. This observational cohort study is conducted by the Kirby Institute and aims to support Australias goal of eliminating HCV by 2030 amid challenges such as declining treatment uptake and impacts from COVID-19. The study focuses on populations with risk factors, including those attending drug treatment clinics, needle and syringe programs, prisons, and other community services. Participants will attend a single visit where they will receive point-of-care HCV antibody testing, providing results within 1 to 20 minutes. If antibody positive, a further point-of-care HCV RNA test will be done to detect active infection. Those with previous HCV infection or treatment will be tested directly with the HCV RNA test. The study does not provide treatment, but participants testing positive for HCV RNA will be connected to standard care pathways for treatment initiation and further clinical evaluation. During the visit, participants will also complete a self-administered survey. Researchers will link survey responses to administrative data to assess long-term health outcomes and the impact of testing scale-up. The primary outcome is the proportion of participants who start HCV treatment within 12 weeks after testing positive. Secondary outcomes include treatment uptake timing, completion rates, cure rates, and cost-effectiveness of testing strategies. Participation involves only one visit, but follow-up data will be collected through linkage to health records over time.

Age: 18Years +All Genders
69 locations